Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888066 · ClinicalTrials.gov registry record · Phase 3
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
A Phase 3 study, sponsored by Vifor Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,195
- Enrollment target
NCT03888066: Completed Phase 3 study, sponsored by Vifor Pharma.
NCT03888066 is a Phase 3 study that has completed, run by Vifor Pharma. The registered enrollment target is 1,195 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03888066, a Phase 3 study, has completed, sponsored by Vifor Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,195 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
Primary Outcome
Adjusted mean changes in serum K+ from Baseline.
Interventions
- DRUG Placebos
- DRUG Patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,195 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 3 |
What the finished NCT03888066 record still lists
NCT03888066 is an interventional study that assigns participants to a tested intervention. Its 1,195 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03888066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03888066 about?
NCT03888066 is a clinical study titled "Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)". The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
What is the current status of trial NCT03888066?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,195 participants. The study started on 2019-04-24. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT03888066?
The interventions under investigation include: Placebos (DRUG), Patiromer (DRUG).
Who is sponsoring clinical trial NCT03888066?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03888066's enrollment target sits among peer trials
1,195 229th of 2000 higher than 1,772 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI